Enlivex Therapeutics is a clinical-stage immunotherapy company that uses macrophage reprogramming to develop cell-based therapy. Their product, Allocetra, is currently in phase II clinical trial to treat organ dysfunction and failure associated with sepsis. Founded in 2005, Enlivex Therapeutics is headquartered in Nes Ziona, Israel.